Want to see SEER full AI Analyst Report?
Top Page
Seer
(NASDAQ:SEER)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(1.52% Upside)
Action:Reiterated
Date:08/19/26
Overall score is constrained primarily by weak financial performance (very large losses and persistent cash burn despite improved gross margin and low leverage). Technical signals are mixed/neutral, while valuation is hard to support with a negative P/E and no dividend yield. The earnings call adds modest support via reaffirmed guidance, strong cash resources and buybacks, but near-term commercial headwinds and YoY revenue decline remain notable risks; the takeover rejection is a secondary, mixed-positive catalyst.
Positive Factors
Scientific validation and intellectual property
Third-party publications, comparative studies and a broad patent portfolio strengthen platform credibility and help defend Seer’s differentiation. These assets can support adoption, licensing opportunities and competitive protection over the medium term.
Negative Factors
Severe operating losses and persistent cash burn
The current revenue base is insufficient to support the cost structure, leaving Seer dependent on its cash reserves and potentially external capital. Continued losses reduce balance-sheet strength over time and make sustainable self-funding dependent on substantial operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Scientific validation and intellectual property
Third-party publications, comparative studies and a broad patent portfolio strengthen platform credibility and help defend Seer’s differentiation. These assets can support adoption, licensing opportunities and competitive protection over the medium term.
Read all positive factors
Seer (SEER) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$111.85M
Dividend YieldN/A
Average Volume (3M)113.15K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth-13.23%
EPS Growth12.29%
CountryUS
Employees124
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.22
Shares Outstanding55,372,017
10 Day Avg. Volume70,395
30 Day Avg. Volume113,152
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside103.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$16.12M
Seer Business Overview & Revenue Model
Company Description
null...
How the Company Makes Money
null...
Seer Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Neutral
The call presented strong scientific, IP and strategic positives — including substantial publication momentum, independent study validation, a robust patent position, healthy cash reserves and sequential revenue improvement — but these were tempered by meaningful near-term commercial and financial challenges: year-over-year revenue decline (~24%), ongoing net losses, negative free cash flow, funding headwinds in the academic market and only modest full-year guidance (~3% growth at midpoint). The message is one of long-term conviction in the technology coupled with a cautious near-term commercial outlook.Positive Updates
Scientific Validation and Publication Momentum
Over 95 publications, preprints and reviews validating the Proteograph Product Suite (approximately an 80% increase over the last 12 months), strengthening third-party credibility and accelerating adoption.
Negative Updates
Year-over-Year Revenue Decline
Total revenue was $3.1 million in Q2 2026 versus $4.1 million in Q2 2025, a decline of approximately 24% year-over-year, driven by lower product and service revenue amid academic and government funding pressures.
Read all updates
Q2-2026 Updates
Positive
Negative
Scientific Validation and Publication Momentum
Over 95 publications, preprints and reviews validating the Proteograph Product Suite (approximately an 80% increase over the last 12 months), strengthening third-party credibility and accelerating adoption.
Read all positive updates
Company Guidance
Seer reaffirmed full‑year 2026 revenue guidance of $16.0–$18.0 million (roughly 3% growth at the midpoint versus full‑year 2025), despite a softer Q2 as management expects H2 revenue growth from increased instrument utilization and consumable pull‑through, population‑scale and ASMS/PRECISE data catalysts, and new commercial leadership; Q2 revenue was $3.1M (up from $2.8M in Q1, down from $4.1M in Q2 2025), total gross profit was $1.5M with a 49% gross margin (52% in Q2 2025; long‑term target 70–75%), total operating expenses were $18.3M (including $1.5M stock‑based comp), Q2 net loss was $16.9M, six‑month free cash flow was approximately −$25.3M, cash and investments totaled $209.5M (management believes sufficient to reach cash‑flow breakeven), and the company repurchased ~200k Class A shares in Q2 at an average $1.68 (≈13.4M total repurchased at a VWAP of $1.86, reducing shares outstanding ~15% with ≈$25.1M of repurchase authorization remaining).Seer Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.85M | 16.12M | 13.95M | 15.18M | 14.69M | 6.39M |
| Gross Profit | 6.41M | 8.01M | 6.83M | 1.45M | 384.00K | -374.00K |
| EBITDA | -64.24M | -71.89M | -80.33M | -80.70M | -87.06M | -67.61M |
| Net Income | -67.96M | -73.60M | -86.60M | -86.28M | -92.97M | -71.17M |
Balance Sheet | ||||||
| Total Assets | 256.64M | 296.08M | 366.60M | 436.27M | 487.93M | 539.14M |
| Cash, Cash Equivalents and Short-Term Investments | 152.85M | 185.90M | 236.41M | 316.22M | 421.24M | 400.07M |
| Total Debt | 22.39M | 23.65M | 25.96M | 28.26M | 29.87M | 23.32M |
| Total Liabilities | 30.96M | 36.78M | 39.03M | 39.37M | 40.94M | 36.22M |
| Stockholders Equity | 225.68M | 259.31M | 327.57M | 396.90M | 446.99M | 502.92M |
Cash Flow | ||||||
| Free Cash Flow | -44.23M | -46.24M | -49.69M | -66.37M | -71.05M | -53.27M |
| Operating Cash Flow | -43.38M | -44.45M | -46.11M | -59.06M | -60.78M | -46.35M |
| Investing Cash Flow | 36.18M | 61.55M | 65.86M | 37.90M | -122.72M | -170.88M |
| Financing Cash Flow | -4.66M | -10.57M | -11.49M | 452.00K | 3.89M | 116.63M |
Seer Technical Analysis
Neutral
1.97
Price Trends
2.01
Positive
1.93
Positive
1.90
Positive
Market Momentum
>-0.01
Positive
44.08
Neutral
17.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Neutral. The current price of 1.97 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.01, and above the 200-day MA of 1.90, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.08 is Neutral, neither overbought nor oversold. The STOCH value of 17.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SEER.
Seer Risk Analysis
Seer disclosed 66 risk factors in its most recent earnings report. Seer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Seer Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $347.44M | -5.20 | -42.80% | ― | ― | 59.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $111.85M | -1.65 | -27.23% | ― | -13.23% | 12.29% | |
48 Neutral | $99.85M | -5.52 | -50.17% | ― | ― | 70.27% | |
47 Neutral | $53.10M | -1.76 | -39.76% | ― | ― | 65.39% | |
45 Neutral | $278.68M | -0.58 | 187.62% | ― | -8.79% | -195.46% | |
43 Neutral | $52.69M | -0.82 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
SEER
Seer
2.01
-0.02
-0.99%
IKT
Inhibikase Therapeutics
2.47
0.63
34.24%
SRZN
Surrozen
24.01
12.33
105.57%
TIL
Instil Bio
7.86
-19.76
-71.54%
TCRX
TScan Therapeutics
0.75
-1.07
-58.79%
CGTX
Cognition Therapeutics
1.06
-1.42
-57.26%
Seer Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Seer Shareholders Back Board Amid Governance Tensions
Neutral
Jul 31, 2026
On July 28, 2026, Seer held its 2026 annual meeting of stockholders, where shareholders elected seven company-nominated directors and rejected three dissident nominees proposed by the Radoff-JEC Group. Investors also ratified Deloitte Touche as a...
Business Operations and StrategyM&A Transactions
Seer Evaluates Competing Acquisition Proposals From Bidder Groups
Neutral
Jul 31, 2026
On July 28 and 29, 2026, Seer received further revised, unsolicited and non-binding proposals from two separate bidder groups to acquire all outstanding shares of its Class A common stock. The Radoff-JEC Group offered $2.55 per share in cash plus ...
Business Operations and StrategyM&A Transactions
Seer Board Rejects CEO’s Undervalued Takeover Proposal
Positive
Jul 20, 2026
On July 20, 2026, Seer, Inc. announced that a special committee of its board, composed of independent directors, had unanimously rejected an unsolicited, non-binding offer from Chair and CEO Omid Farokhzad dated July 1, 2026. The proposal sought t...
Business Operations and StrategyM&A Transactions
Seer CEO Makes Insider Proposal to Take Company Private
Neutral
Jul 2, 2026
On July 2, 2026, Seer, Inc. announced it had received an unsolicited, non-binding proposal from its chair and chief executive officer, Omid Farokhzad, M.D., to acquire all outstanding shares of the company’s Class A common stock for $2.45 pe...
Business Operations and StrategyM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Seer Board Rejects Revised Radoff-JEC Acquisition Proposal
Neutral
May 22, 2026
On May 21, 2026, Seer, Inc. announced that its board of directors unanimously rejected a further revised unsolicited, non-binding acquisition proposal submitted on May 14, 2026, by the Radoff-JEC Group to buy all outstanding Class A shares for $2....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.